Cargando…

Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Detalles Bibliográficos
Autores principales:	Petrillo, Alessandra, Ip, Andrew, Della Pia, Alexandra, Gill, Sarvainder, Zenreich, Joshua, Gutierrez, Martin, McNeill, Ann, Feldman, Tatyana, Leslie, Lori A., Goy, Andre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208873/ https://www.ncbi.nlm.nih.gov/pubmed/35747844 http://dx.doi.org/10.1097/HS9.0000000000000719

Ejemplares similares

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
por: D’Rozario, James, et al.
Publicado: (2019)

Polatuzumab‐bendamustine‐rituximab as bridge to CD19‐directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax
por: Perriello, Vincenzo Maria, et al.
Publicado: (2023)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
por: Handunnetti, Sasanka, et al.
Publicado: (2021)

Ibrutinib for rituximab-refractory Waldenström macro-globulinemia
por: Gavriatopoulou, Maria, et al.
Publicado: (2017)

Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias
por: Nikitin, Eugene, et al.
Publicado: (2023)

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
por: Wang, Michael, et al.
Publicado: (2021)

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
por: de Vos, S, et al.
Publicado: (2018)

Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
por: Barbier, Michaela, et al.
Publicado: (2021)

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
por: Seymour, John F., et al.
Publicado: (2022)

Ibrutinib and rituximab induced rapid response in refractory Richter syndrome
por: Lamar, Zanetta, et al.
Publicado: (2015)

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
por: Kornauth, Christoph, et al.
Publicado: (2021)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
por: Ferrarini, Isacco, et al.
Publicado: (2022)

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma
por: Herrera, Alex F., et al.
Publicado: (2019)

Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
por: Ren, Liangliang, et al.
Publicado: (2021)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
por: Ehsan, Hamid, et al.
Publicado: (2021)

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
por: Zeidan, Amer M., et al.
Publicado: (2022)

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
por: Daver, Naval G., et al.
Publicado: (2023)

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma
por: Timmerman, John, et al.
Publicado: (2020)

Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
por: Denlinger, Nathan M, et al.
Publicado: (2018)

P646: VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
por: Scarfò, Lydia, et al.
Publicado: (2023)

Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
por: Laribi, Kamel, et al.
Publicado: (2022)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.
por: Le Gouill, Steven, et al.
Publicado: (2023)

The iR(2) regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2022)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
por: Vacirca, Jeffrey L., et al.
Publicado: (2013)

Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open‐label phase 3 study
por: Huang, Xiaojun, et al.
Publicado: (2018)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease
por: Benedetti, Edoardo, et al.
Publicado: (2023)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
por: Brancati, Serena, et al.
Publicado: (2021)

Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab
por: Ito, Yuta, et al.
Publicado: (2018)

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
por: Richardson, Paul G., et al.
Publicado: (2018)

PB1736: CLINICAL ANALYSIS OF VENETOCLAX-BASED IN THE TREATMENT OF ADULT RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: LI, Jing, et al.
Publicado: (2023)

Scedosporium apiospermum brain abscesses in a patient receiving ibrutinib and venetoclax
por: Figueroa, Rocio, et al.
Publicado: (2020)

Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
por: Murayama, Kayoko, et al.
Publicado: (2022)

Venetoclax-Rituximab Treatment of Relapsed/Refractory CLL During the COVID-19 Pandemic: A Real-Life Experience in Selected Central-Southern Italian Regions
por: Molica, Stefano, et al.
Publicado: (2021)

Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
por: Fraser, Graeme A.M., et al.
Publicado: (2020)

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7t74f9k6djk4flckqqaii0lnpd